Navigation Links
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive data from a Phase II clinical study of Rituxan(R) (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells.

"There remains a great need for safe and effective treatments for patients with RRMS," said Stephen Hauser, MD, Professor and Chair, Department of Neurology, University of California, San Francisco. "These Phase II results are very encouraging and suggest B-cells play a key role in MS. They also lend support to the concept that selective targeting of B-cells may be an important approach to treating this debilitating disease."

In this Phase II double-blind, placebo-controlled study that evaluated the safety and efficacy of Rituxan in adult patients with RRMS, 104 patients were randomized to receive either a single treatment course of Rituxan (two infusions separated by two weeks) or placebo. The primary endpoint was defined as the total number of gadolinium-enhancing T1 lesions at weeks 12, 16, 20 and 24, as measured by serial MRI scans of the brain. The total number of gadolinium lesions at weeks 12, 16, 20 and 24 was statistically significantly reduced in patients receiving Rituxan compared to those receiving placebo (p less than 0.0001). At week 24, the total cumulative mean number of gadolinium lesions per patient was reduced by 91 percent, to 0.5 in the Rituxan-treated group from 5.5 in the placebo group.

In addition, the proportion of patients with relapses over 24 weeks in the Rituxan-treated arm was 14.5 percent compared to 34.3 percent in the placebo arm (58 percent relative reduction) (p = 0.0238).

With the exception of infusion associated adverse events,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/27/2015)... 27, 2015 Research and ... the  "North America Portable X Ray Devices Market ...  report to their offering.       (Logo: ... market for Portable X-Ray Devices is ... 2014 to 2020 X-Ray is a ...
(Date:5/27/2015)... May 27, 2015  LumiThera Inc., a developmental ... (PBM) treatment for ocular disorders and disease, announced ... Washington State Life Sciences Discovery Fund (LSDF) ... of the LSDF matching grants worth $500,000 to ... subjects with dry age-related macular degeneration (AMD). ...
(Date:5/27/2015)... and Markets( http://www.researchandmarkets.com/research/ljsxt8/asia_pacific ) has announced the addition of the ... Trends And Forecasts (2014 - 2019)" company profile to ... market for Portable X-Ray Devices is expected to grow ... X-Ray is a form of electromagnetic radiation which is used ... need of point of care diagnostics has led to the ...
Breaking Medicine Technology:North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2LumiThera Receives LSDF Commercialization Grant Award 2Asia Pacific Portable X Ray Devices Market 2015 - Trends And Forecasts to 2019 2
... HistoRx, the leader in quantitative immunohistochemistry, has earned ... elements of digital microscopy standardization.  Combined with patents ... & Trademark Office advance the Company,s proprietary position ... dominant role in the industry.  ...
... Feb. 28, 2012  On February 28th, 2012, the New ... those interested in speaking at its 2012 Digital Health ... York City,s Pier Sixty. At NYeC,s ... New York City—over 600 healthcare providers, healthcare technology companies, ...
Cached Medicine Technology:HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 2HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 3Call for Speakers: New York's Digital Health Conference 2012 2
(Date:5/27/2015)... Continuing its commitment to finding a cure and ... SmartPractice® donated $25,000 to HonorHealth Breast Health ... President of Human Resources Meg Mosher and SmartScrubs Director ... Paulla Miller, Sherry Gage, Dr. Linda Greer and Ginger ... April 30. The center is located at 19646 North ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Dr. Omar ... based in Stamford, CT has been selected as part ... first physicians nationwide (and the only physician in Connecticut) ... which allows for the removal of submental fat (double ... no recovery time, no surgery and minimal risks. Dr. ...
(Date:5/27/2015)... NJ (PRWEB) May 27, 2015 ... Network (BCAN) , whose mission is to advance research, ... cancer, have joined forces to battle the fifth most ... in the bladder’s lining start to grow out of ... and their families at every stage of the cancer ...
(Date:5/27/2015)... CompanionDx announced that its abstract “Role ... personalized cancer therapy: Non-small cell lung cancer (NSCLC) case ... Oncology (ASCO) as part of their annual meeting, May ... and clinical data used for the study was obtained ... reports improved patient outcomes from a preliminary analysis of ...
(Date:5/27/2015)... Phoenix, Arizona (PRWEB) May 27, 2015 ... use of their advanced programmatic marketing technology, they have ... provides advertising support on a regional level for seven ... Honda's marketing was through television and radio media. In ... and, with the help of Genius Monkey , ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2
... up to offer customized map solutions. , ... Seattle ... Mapscape B.V. have announced a working relationship that will allow mutual ... solution provided by both companies. , , ,In this relationship, Birdstep ...
... city kids moving, study finds , , FRIDAY, Nov. 14 (HealthDay ... city kids keep excess pounds at bay, according to a ... snapshots in time, and shown that for children in densely ... of obesity. Our new study of over 3,800 inner-city children ...
... treatment and outcomes are different among races , , FRIDAY, Nov. ... have a different genetic makeup in blacks than in whites, ... different among races, a new study says. , In ... of the epidermal growth factor receptor (EGFR) gene and fewer ...
... An intra cellular pathway not previously linked to breast ... is highly lethal and disproportionately over-represented in African American ... destroy proteins and represents a class of genes called ... cells degrade the tumor suppressor gene p27 by making ...
... in Lowering High Blood Pressure Naturally. , ... Phoenix, ... that specializes in all-natural life improvement products, announced the release of ... :Guided Breathing for Low Blood Pressure, this week., , , , ...
... patients more time, developers say , , FRIDAY, Nov. 14 ... developed a technology that can rapidly send an icy ... protect specific organs during certain health emergencies. , ... body through a small intravenous catheter directly into a ...
Cached Medicine News:Health News:Birdstep Technology Partners with Mapscape to Offer RDM Embedded Content Solution for Navigation Systems 2Health News:Birdstep Technology Partners with Mapscape to Offer RDM Embedded Content Solution for Navigation Systems 3Health News:Greener Neighborhoods Mean Slimmer Children 2Health News:Lung Cancer Genetics Different in Black Patients: Study 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 3Health News:High Blood-Pressure Patients Can See Improvement Through Guided Breathing 2Health News:IV 'Ice Slurry' Quickly Cools Body for Surgeries 2
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most comprehensive ... Eraser Instruments for Cataract incision, Glaucoma ... discrete coagulation is achieved with minimal ... necrosis. Straight eraser styles are available ...
Medicine Products: